Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy

Core Insights - Dren Bio has entered a strategic collaboration with Sanofi to develop a next-generation B-cell depleting therapy for autoimmune diseases [1][2] - The collaboration builds on Sanofi's earlier acquisition of Dren Bio's DR-0201 program, now known as SAR448501, which is currently in phase 1 studies showing robust B-cell depletion [2][4] Company Overview - Dren Bio is a clinical-stage biopharmaceutical company focused on developing first-in-class antibody therapeutics for cancer and autoimmune diseases [4] - The company's proprietary Targeted Myeloid Engager and Phagocytosis Platform is designed to induce potent depletion of disease-causing agents through multispecific antibodies [4] Financial Terms of the Agreement - Dren Bio will receive an upfront payment of $100 million and is eligible for up to $1.7 billion in milestone payments related to development, regulatory, and commercial achievements [3] - The agreement includes a U.S. profit/loss sharing option, allowing Dren Bio to co-fund 40% of global development costs in exchange for U.S. co-promotion rights and a 50/50 share of U.S. profits and losses [3]